These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36914553)

  • 1. Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort.
    Arlegui H; Mahé E; Richard MA; De Rycke Y; Viguier M; Beylot-Barry M; Dupuy A; Beneton N; Joly P; Jullien D; Bachelez H; Sbidian É; Chosidow O; Paul C; Tubach F;
    Ann Dermatol Venereol; 2023 Jun; 150(2):101-108. PubMed ID: 36914553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 and adherence to biologic therapies for psoriasis: An analysis of nationwide pharmacy claims data.
    He M; Ferris LK; Gabriel N; Tadrous M; Hernandez I
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1213-1218. PubMed ID: 36282925
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID).
    Kwee KV; Murk JL; Yin Q; Visch MB; Davidson L; de Jong EMGJ; van den Reek JMPA; Tjioe M
    J Dermatolog Treat; 2023 Dec; 34(1):2161297. PubMed ID: 36545844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
    Sadeghinia A; Daneshpazhooh M
    Dermatol Ther; 2021 Jan; 34(1):e14498. PubMed ID: 33141519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Concordance of Telemedicine as Compared With Face-to-Face Care in Primary Health Care Clinics in Rural India: Randomized Crossover Trial.
    Verma N; Buch B; Taralekar R; Acharya S
    JMIR Form Res; 2023 Jun; 7():e42775. PubMed ID: 37130015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey.
    Quirke-McFarlane S; Weinman J; Cook ES; Yiu ZZN; Dand N; Langan SM; Bechman K; Tsakok T; Mason KJ; McAteer H; Meynell F; Coker B; Vincent A; Urmston D; Vesty A; Kelly J; Lancelot C; Moorhead L; Barbosa IA; Bachelez H; Capon F; Contreras CR; De La Cruz C; Di Meglio P; Gisondi P; Jullien D; Lambert J; Naldi L; Puig L; Spuls P; Torres T; Warren RB; Waweru H; Galloway JB; Griffiths CEM; Barker JN; Norton S; Smith CH; Mahil SK;
    Br J Dermatol; 2023 Apr; 188(5):610-617. PubMed ID: 36763806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France.
    Penso L; Dray-Spira R; Weill A; Zureik M; Sbidian E
    Br J Dermatol; 2022 Jan; 186(1):59-68. PubMed ID: 34310699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis [Formula: see text].
    Ladda M; Lynde C; Fleming P
    J Cutan Med Surg; 2020; 24(6):625-632. PubMed ID: 32757760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model.
    Pople D; Monk EJM; Evans S; Foulkes S; Islam J; Wellington E; Atti A; Hope R; Robotham J; Hopkins S; Brown CS; Hall VJ;
    BMJ; 2022 Jul; 378():e070379. PubMed ID: 35858689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter to the Editor: THE IMPACT OF THE COVID-19 PANDEMIC ON SCHIZOPHRENIA PATIENTS.
    Hoşgelen EI; Alptekin K
    Turk Psikiyatri Derg; 2021; 32(3):219-221. PubMed ID: 34750798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter to the Editor: THE IMPACT OF THE COVID-19 PANDEMIC ON SCHIZOPHRENIA PATIENTS.
    Hoşgelen EI; Alptekin K
    Turk Psikiyatri Derg; 2021; 32(3):219-221. PubMed ID: 34637131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic.
    Rob F; Hugo J; Tivadar S; Boháč P; Gkalpakiotis S; Vargová N; Arenbergerová M; Hercogová J
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):e682-e684. PubMed ID: 32594549
    [No Abstract]   [Full Text] [Related]  

  • 13. Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.
    Kado S; Kamiya K; Kishimoto M; Maekawa T; Kuwahara A; Sugai J; Komine M; Ohtsuki M
    J Dermatol; 2021 Dec; 48(12):1907-1912. PubMed ID: 34549456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the COVID-19 pandemic on biologic treatment in psoriasis patients: A single-center retrospective study in Japan.
    Uchida H; Kamata M; Egawa S; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2022 Jun; 49(6):624-628. PubMed ID: 35319126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical management of psoriasis patients during the COVID-19 pandemic.
    Chat VS; Uppal SK; Kearns DG; Wu JJ
    J Dermatolog Treat; 2022 Mar; 33(2):1166-1167. PubMed ID: 32568009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.
    Mahil SK; Dand N; Mason KJ; Yiu ZZN; Tsakok T; Meynell F; Coker B; McAteer H; Moorhead L; Mackenzie T; Rossi MT; Rivera R; Mahe E; Carugno A; Magnano M; Rech G; Balogh EA; Feldman SR; De La Cruz C; Choon SE; Naldi L; Lambert J; Spuls P; Jullien D; Bachelez H; McMahon DE; Freeman EE; Gisondi P; Puig L; Warren RB; Di Meglio P; Langan SM; Capon F; Griffiths CEM; Barker JN; Smith CH;
    J Allergy Clin Immunol; 2021 Jan; 147(1):60-71. PubMed ID: 33075408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic.
    Cazzaniga S; Naldi L
    Br J Dermatol; 2022 Jan; 186(1):7-8. PubMed ID: 34726776
    [No Abstract]   [Full Text] [Related]  

  • 18. The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020.
    ;
    Euro Surveill; 2020 Dec; 25(50):. PubMed ID: 33334400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of incidence of chilblain-like lesions in children during the first year of COVID-19 pandemic.
    Bascuas-Arribas M; Andina-Martinez D; Añon-Hidalgo J; Alonso-Cadenas JA; Hernandez-Martin A; Lamagrande-Casanova N; Noguero-Morel L; Mateos-Mayo A; Colmenero-Blanco I; Torrelo A
    Pediatr Dermatol; 2022 Mar; 39(2):243-249. PubMed ID: 35129855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common communicable diseases in the general population in France during the COVID-19 pandemic.
    Launay T; Souty C; Vilcu AM; Turbelin C; Blanchon T; Guerrisi C; Hanslik T; Colizza V; Bardoulat I; Lemaître M; Boëlle PY
    PLoS One; 2021; 16(10):e0258391. PubMed ID: 34634090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.